REMEGEN(09995) reported a net loss attributable to equity holders of the company of 1.468 billion yuan in 2024, a decrease of 2.9% year-on-year.

REMEGEN (09995) released its 2024 annual performance report, with operating income of 1.715 billion yuan (RMB), up 58.40% year-on-year; net loss attributable to owners of the parent company was 1.468 billion yuan, narrowing by 2.9% year-on-year; basic loss per share was 2.73 yuan. During the period, operating income increased by 58.40% year-on-year, mainly due to an increase in sales of injection Tyrosine Tys and injection Vediriximab, resulting in increased sales revenue.